AR066372A1 - Formulaciones de aminoacidos n-halogenados con compuestos antiinflamatorios - Google Patents
Formulaciones de aminoacidos n-halogenados con compuestos antiinflamatoriosInfo
- Publication number
- AR066372A1 AR066372A1 ARP080101843A ARP080101843A AR066372A1 AR 066372 A1 AR066372 A1 AR 066372A1 AR P080101843 A ARP080101843 A AR P080101843A AR P080101843 A ARP080101843 A AR P080101843A AR 066372 A1 AR066372 A1 AR 066372A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- halogenated amino
- amino acid
- inflammatory compound
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 150000001413 amino acids Chemical class 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 abstract 7
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- NMMHHSLZJLPMEG-UHFFFAOYSA-N 2-(chloroamino)ethanesulfonic acid Chemical compound OS(=O)(=O)CCNCl NMMHHSLZJLPMEG-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical class 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 239000000043 antiallergic agent Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulacion que tiene actividad antimicrobiana, que comprende un aminoácido N-halogenado y un compuesto antiinflamatorio. Esta memoria descriptiva además describe métodos para el tratamiento de una infeccion de tejido, que comprenden el contacto deltejido infectado con una cantidad farmacéuticamente eficaz de una formulacion que comprende un aminoácido N-halogenado y un compuesto antiinflamatorio. Esta memoria descriptiva también describe un método para el tratamiento de infeccionesrespiratorias, que comprende el contacto del sitio de la infeccion respiratoria con una cantidad farmacéuticamente eficaz de una formulacion que comprende un aminoácido N-halogenado y un compuesto antiinflamatorio. Reivindicacion 2: La formulacionde la reivindicacion 1, donde el compuesto antiinflamatorio se selecciona del grupo que consiste en: AINE, agentes antialérgicos y sus combinaciones. Reivindicacion 4: La formulacion de la reivindicacion 3, donde la clorotaurina es 2,2-dimetil-N,N-diclorotaurina de sodio. Reivindicacion 5: La formulacion de la reivindicacion 3, donde el aminoácido N-halogenado forma un par ionico con un componente de dicha formulacion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91527707P | 2007-05-01 | 2007-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066372A1 true AR066372A1 (es) | 2009-08-12 |
Family
ID=39495776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101843A AR066372A1 (es) | 2007-05-01 | 2008-04-30 | Formulaciones de aminoacidos n-halogenados con compuestos antiinflamatorios |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080275122A1 (es) |
| EP (1) | EP2139519A1 (es) |
| JP (1) | JP2010526085A (es) |
| KR (1) | KR20100017159A (es) |
| CN (1) | CN101687041A (es) |
| AR (1) | AR066372A1 (es) |
| AU (1) | AU2008247788A1 (es) |
| BR (1) | BRPI0810962A2 (es) |
| CA (1) | CA2684186A1 (es) |
| CL (1) | CL2008001282A1 (es) |
| MX (1) | MX2009011818A (es) |
| RU (1) | RU2009144286A (es) |
| TW (1) | TW200901957A (es) |
| UY (1) | UY31058A1 (es) |
| WO (1) | WO2008137444A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110151025A1 (en) * | 2008-04-10 | 2011-06-23 | Novabay Pharmaceuticals, Inc. | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections |
| US20110091570A1 (en) * | 2008-04-15 | 2011-04-21 | Waldemar Gottardi | Compositions and Devices for Antisepsis and Anticoagulation |
| EP2720665A2 (en) | 2011-06-15 | 2014-04-23 | Rls Global Ab | Detection and removal of carious dentin tissue. |
| SE536581C2 (sv) | 2012-07-24 | 2014-03-11 | Rls Global Ab | Ett kit för behandling av sår eller liknande och ett preparat och metoder därav |
| US20140227201A1 (en) * | 2013-02-13 | 2014-08-14 | Novabay Pharmaceuticals, Inc. | Antimicrobial Gel Formulations |
| KR102253324B1 (ko) * | 2019-11-27 | 2021-05-18 | 단디바이오사이언스 주식회사 | 호흡기 질환의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4910225A (en) * | 1988-01-27 | 1990-03-20 | Senju Pharmaceutical Co., Ltd. | Locally administrable therapeutic composition for inflammatory disease |
| US5421818A (en) * | 1993-10-18 | 1995-06-06 | Inner Ear Medical Delivery Systems, Inc. | Multi-functional inner ear treatment and diagnostic system |
| US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| US6156728A (en) * | 1996-11-01 | 2000-12-05 | Genentech, Inc. | Treatment of inner ear hair cells |
| WO2001089495A2 (en) * | 2000-05-19 | 2001-11-29 | Alcon Laboratories, Inc. | Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose |
| PE20020578A1 (es) * | 2000-10-10 | 2002-08-14 | Upjohn Co | Una composicion de antibiotico topico para el tratamiento de infecciones oculares |
| AU2002364051A1 (en) * | 2002-01-24 | 2003-09-02 | Children's Medical Center Corporation | Anti-cancer combination and use thereof |
| BRPI0413660A (pt) * | 2003-08-18 | 2006-10-24 | Novacal Pharmaceuticals Inc | Aminoácidos n,n-di-alogenado e derivados |
| TWI386201B (zh) * | 2005-01-25 | 2013-02-21 | Novabay Pharmaceuticals Inc | Ｎ-鹵化胺基酸、ｎ，ｎ-二鹵化胺基酸與其衍生物；以及使用其之組合物與方法 |
| UY31059A1 (es) * | 2007-05-01 | 2008-10-31 | Alcon Res Ltd | Formulaciones de aminoacido n-halogenado |
-
2008
- 2008-04-29 UY UY31058A patent/UY31058A1/es not_active Application Discontinuation
- 2008-04-30 CN CN200880013887A patent/CN101687041A/zh active Pending
- 2008-04-30 WO PCT/US2008/061956 patent/WO2008137444A1/en active Application Filing
- 2008-04-30 US US12/112,352 patent/US20080275122A1/en not_active Abandoned
- 2008-04-30 BR BRPI0810962-1A2A patent/BRPI0810962A2/pt not_active IP Right Cessation
- 2008-04-30 JP JP2010506590A patent/JP2010526085A/ja not_active Withdrawn
- 2008-04-30 EP EP08780580A patent/EP2139519A1/en not_active Withdrawn
- 2008-04-30 CA CA002684186A patent/CA2684186A1/en not_active Abandoned
- 2008-04-30 RU RU2009144286/15A patent/RU2009144286A/ru not_active Application Discontinuation
- 2008-04-30 AU AU2008247788A patent/AU2008247788A1/en not_active Abandoned
- 2008-04-30 TW TW097115859A patent/TW200901957A/zh unknown
- 2008-04-30 AR ARP080101843A patent/AR066372A1/es not_active Application Discontinuation
- 2008-04-30 KR KR1020097024160A patent/KR20100017159A/ko not_active Application Discontinuation
- 2008-04-30 MX MX2009011818A patent/MX2009011818A/es unknown
- 2008-05-02 CL CL2008001282A patent/CL2008001282A1/es unknown
-
2010
- 2010-04-26 US US12/767,420 patent/US20100210730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2684186A1 (en) | 2008-11-13 |
| BRPI0810962A2 (pt) | 2015-01-27 |
| KR20100017159A (ko) | 2010-02-16 |
| US20080275122A1 (en) | 2008-11-06 |
| RU2009144286A (ru) | 2011-06-10 |
| US20100210730A1 (en) | 2010-08-19 |
| WO2008137444A1 (en) | 2008-11-13 |
| MX2009011818A (es) | 2009-11-13 |
| TW200901957A (en) | 2009-01-16 |
| JP2010526085A (ja) | 2010-07-29 |
| UY31058A1 (es) | 2008-10-31 |
| AU2008247788A1 (en) | 2008-11-13 |
| EP2139519A1 (en) | 2010-01-06 |
| CN101687041A (zh) | 2010-03-31 |
| CL2008001282A1 (es) | 2009-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117547T1 (el) | Ενωση πυραζολοκινολινης | |
| AR066372A1 (es) | Formulaciones de aminoacidos n-halogenados con compuestos antiinflamatorios | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| CL2007001427A1 (es) | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po | |
| BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| EA201100873A1 (ru) | Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| AR030068A1 (es) | Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet | |
| DE602006003415D1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen | |
| AR024159A1 (es) | Nuevo uso de compuestos como agentes antibacterianos | |
| PA8748101A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
| BRPI0607796A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica | |
| ECSP066608A (es) | Suspensiones acuosas de ciclesonide para nebulización | |
| CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
| AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
| UY31609A1 (es) | "(-) ácido 2-[1-(7-metil-2-(morfolin-4-il) 4-oxo-4h-pirido[1,2-a]pirimidin-9-il)etilamino]benzoico enantioméricamente puro, su uso en terapia médica, y una composición farmacéutica que lo comprende-026." | |
| BRPI0617655A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica | |
| CY1113670T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης | |
| CY1116831T1 (el) | ΧΡΗΣΗ 24-norUDCA | |
| PE20211391A1 (es) | Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-acido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmaceutico | |
| CL2008001279A1 (es) | Metodo para mejorar la actividad antimicrobiana de una formulacion que comprende un aminoacido n-halogenado que comprende un agente de transferencia de fase; formulacion; metodo para desinfectar superficies y lentes de contacto; metodo para tratar una infeccion de tejido y para tratar infecciones respiratorias. | |
| AR068307A1 (es) | Formulaciones de aminoacidos n-halogenados y metodos para la limpieza y desinfeccion | |
| GT200600524A (es) | Preparacion de gamma-aminoacidos que tienen afinidad por la proteina alfa-2-delta | |
| BRPI0703970A2 (pt) | tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona | |
| BR112014002885A2 (pt) | uso de composto orgânico para o tratamento da síndrome de noonan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |